Sweeping changes phase in slowly for most, but insurers, hospitals, drug companies, employers, workers, medical device makers
and more will eventually feel impact.
Drugmakers and insurers could gain millions of customers under the legislation, but the industry also will pay new fees and
face stricter rules that may shrink profit and fuel mergers.
But excluding special charges, Warsaw-based orthopedic implant maker grows profits 5 percent, easily beating expectations
of Wall
Street.
Roche Diagnostics named a new CEO for its North American operations Tuesday to replace Michael Tillmann, who resigned on Friday.
FAST Diagnostics LLC said initial human trials on its method to measure kidney function faster and more accurately than existing
techniques could begin as early as next year, with commercialization following by 2012.
The Indiana-based orthopedic implant maker plans to use the proceeds to pay down debt and for general corporate purposes.
Bloomington-based Cook Group Inc. might have to cut as many as 1,000 local jobs if Congress enacts a tax on medical devices
to pay for health care reform, company founder Bill Cook said in an interview.
Bloomington-based Cook Group Inc. could find itself cutting as many as 1,000 local jobs if Congress enacts a tax on
medical devices to pay for health care reform, company founder Bill Cook said in an interview.
A new group expected to develop the orthopedic implants industry in Warsaw will be able to proceed now that Indianapolis-based
Lilly Endowment Inc. is putting $7 million behind it, according to an announcement this morning.
The launch of the orthopedics not-for-profit OrthoWorx is quite an accomplishment in Warsaw, where some of the world’s
biggest companies fight tooth-and-nail.
Indianapolis-based FAST Diagnostics, a developer of a method to quickly measure kidney function, announced today that it has
received $1 million in federal funding.
Bloomington-based Cook Medical has won European approval for a new artery-opening device for the legs that it predicts will
be a blockbuster.
Industry groups in the life sciences, medical and information technology realms have helped lure companies to the region
and foster upstarts. Funding is almost always an issue, but it’s not the only barrier. Getting medical
devices to market often requires product design, development and marketing resources that aren’t
always apparent to upstarts.
Biomet Inc. yesterday reported a $170.9 million loss in its fiscal fourth quarter as the result of more than $300 million
in special charges.
Purdue University researcher Philip Low, also the chief science officer for West Lafayette-based Endocyte Inc., has developed
a prostate cancer “homing device” to help anti-cancer agents specifically target prostate
cancer tumors.
Taking science from the laboratory to the commercial market takes too much time and is littered with potential pitfalls along the way.
In a state steeped in advanced research that spawns biomedical companies by the dozen, Apricity LLC is preposterously low-tech,
given that its latest product is nothing more than a warm blanket.
Catheter Research Inc. now is flying high—even in the midst of a bad economy.
Indianapolis-based medical-device startup NICO Corp. has raised $1.73 million from investors.
Economists call it a “virtuous cycle” when successful entrepreneurs plow their gains into new businesses. Jim Pearson calls
it another day on the job. The former Suros Surgical Systems Inc. CEO is attempting to repeat what he already has done: Build
a company to bring a promising medical device all the way from the drawing board to the market.
